Healthcare trends

As of July 2019, 3.4 million people are affected by alpha-1 antitrypsin deficiency worldwide. The disorder is found to affect populations in all the regions of the world. The market is dominated by numerous established players. The key players are involved in product launches, strategic collaborations, and awareness programs to strengthen their market positions. For instance, in November 2018, Grifols S. A. launched the AlfaCare therapy program for training and counseling of patients diagnosed with alpha-1 antitrypsin deficiency. Registering a  CAGR  of  10.50%,  the global  Alpha-1 Antitrypsin Deficiency Treatment Market  is expected to grow from  USD 1,464.1 million  in 2018 to  USD 2,914.7 million  by  2025 . Alpha-1 Antitrypsin Deficiency Treatment   Market-Key Players: Kamada Pharmaceuticals CSL Behring LLC Grifols Takeda Pharmaceutical Company Limited GlaxoSmithKline plc Boehringer Ingelheim GmbH AstraZe...

As of July 2019, 3.4 million people are affected by alpha-1 antitrypsin deficiency worldwide. The disorder is found to affect populations in all the regions of the world. The market is dominated by numerous established players. The key players are involved in product launches, strategic collaborations, and awareness programs to strengthen their market positions. For instance, in November 2018, Grifols S. A. launched the AlfaCare therapy program for training and counseling of patients diagnosed with alpha-1 antitrypsin deficiency. Registering a  CAGR  of  10.50%,  the global  Alpha-1 Antitrypsin Deficiency Treatment Market  is expected to grow from  USD 1,464.1 million  in 2018 to  USD 2,914.7 million  by  2025 . Alpha-1 Antitrypsin Deficiency Treatment   Market-Key Players: Kamada Pharmaceuticals CSL Behring LLC Grifols Takeda Pharmaceutical Company Limited GlaxoSmithKline plc Boehringer Ingelheim GmbH Ast...